Market Overview:
The global phenylketonuria medication market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of phenylketonuria, rising awareness about PKU treatment, and technological advancements in the field of phenylketonuria medication. The global phenylketonuria medication market is segmented on the basis of type into Kuvan, Palynziq, and others. On the basis of application, it is segmented into hospitals, clinics, and others. Geographically, it is segmented into North America, Latin America Europe Asia Pacific Middle East & Africa (MEA).
Product Definition:
Phenylketonuria Medication is a medication used to treat phenylketonuria, a condition in which the body cannot break down the amino acid phenylalanine. Phenylketonuria Medication helps to prevent high levels of phenylalanine from building up in the blood, which can damage the brain.
Kuvan:
The global kuvan market size was valued at USD 62.5 million in 2016 and is expected to grow at a CAGR of XX% over the forecast period.
Palynziq:
Palynziq (PALZN03) is a novel drug for the treatment of PKU. It is an all-natural, plant-based, and non-GMO feedstock that has been optimized for maximum yield with high purity and quality. The company has carried out extensive research to show that palynziq can be used as a safe and effective treatment in PKU patients across the globe.
The clinical trial was designed to test the safety.
Application Insights:
The hospital application segment led the global phenylketonuria medication market in 2017. The others segment include private clinics and hospitals; however, a significant share is accounted for by the hospital segment due to factors such as large patient base with PKU along with other related complications requiring dietary management.
Clinical trials have proven that these restricted diet plans help improve mental alertness in children suffering from this condition along with other benefits such as improvement in vision & hearing, reduction in anxiety & irritability among many others.
Regional Analysis:
North America was the largest market for the global DPKD medication in 2016. The presence of well-established healthcare facilities, favorable reimbursement policies and increasing awareness about PKU treatment are some of the major factors contributing to its growth. In addition, rising incidence of obesity is also expected to drive demand for these drugs in this region over the forecast period.
Asia Pacific is estimated to be one of fastest growing regions during the forecast period owing to high unmet clinical needs and availability of effective therapies at a low cost coupled with improving healthcare infrastructure in emerging countries such as China and India.
Growth Factors:
- Increasing prevalence of phenylketonuria (PKU)
- Growing awareness about PKU and its treatment options
- Rising demand for novel and effective therapies for PKU
- Technological advancements in phenylketonuria medication market
- Growing number of clinical studies on new phenylketonuria medications
Scope Of The Report
Report Attributes
Report Details
Report Title
Phenylketonuria Medication Market Research Report
By Type
Kuvan, Palynziq, Others
By Application
Hospital, Clinic, Others
By Companies
Biomarin, Vitaflo, Mead Johnson, Nutricia, Abbott, Dr. Schär, Prominmetabolics, Cambrooke, Juvela, Firstplay Dietary, PKU Perspectives
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Phenylketonuria Medication Market Report Segments:
The global Phenylketonuria Medication market is segmented on the basis of:
Types
Kuvan, Palynziq, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biomarin
- Vitaflo
- Mead Johnson
- Nutricia
- Abbott
- Dr. Schär
- Prominmetabolics
- Cambrooke
- Juvela
- Firstplay Dietary
- PKU Perspectives
Highlights of The Phenylketonuria Medication Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Kuvan
- Palynziq
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Phenylketonuria Medication Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Phenylketonuria medication is a drug that helps people with the disorder control their blood levels of phenylalanine. Phenylketonuria is a rare genetic disorder that affects the body's ability to break down phenylalanine, which can lead to serious health problems if left untreated. People with this condition need to take special precautions to avoid high levels of phenylalanine in their bloodstreams, including taking medications and following dietary guidelines.
Some of the key players operating in the phenylketonuria medication market are Biomarin, Vitaflo, Mead Johnson, Nutricia, Abbott, Dr. Sch¤r, Prominmetabolics, Cambrooke, Juvela, Firstplay Dietary, PKU Perspectives.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Phenylketonuria Medication Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Phenylketonuria Medication Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Phenylketonuria Medication Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Phenylketonuria Medication Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Phenylketonuria Medication Market Size & Forecast, 2018-2028
4.5.1 Phenylketonuria Medication Market Size and Y-o-Y Growth
4.5.2 Phenylketonuria Medication Market Absolute $ Opportunity
Chapter 5 Global Phenylketonuria Medication Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Phenylketonuria Medication Market Size Forecast by Type
5.2.1 Kuvan
5.2.2 Palynziq
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Phenylketonuria Medication Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Phenylketonuria Medication Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Phenylketonuria Medication Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Phenylketonuria Medication Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Phenylketonuria Medication Analysis and Forecast
9.1 Introduction
9.2 North America Phenylketonuria Medication Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Phenylketonuria Medication Market Size Forecast by Type
9.6.1 Kuvan
9.6.2 Palynziq
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Phenylketonuria Medication Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Phenylketonuria Medication Analysis and Forecast
10.1 Introduction
10.2 Europe Phenylketonuria Medication Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Phenylketonuria Medication Market Size Forecast by Type
10.6.1 Kuvan
10.6.2 Palynziq
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Phenylketonuria Medication Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Phenylketonuria Medication Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Phenylketonuria Medication Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Phenylketonuria Medication Market Size Forecast by Type
11.6.1 Kuvan
11.6.2 Palynziq
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Phenylketonuria Medication Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Phenylketonuria Medication Analysis and Forecast
12.1 Introduction
12.2 Latin America Phenylketonuria Medication Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Phenylketonuria Medication Market Size Forecast by Type
12.6.1 Kuvan
12.6.2 Palynziq
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Phenylketonuria Medication Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Phenylketonuria Medication Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Phenylketonuria Medication Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Phenylketonuria Medication Market Size Forecast by Type
13.6.1 Kuvan
13.6.2 Palynziq
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Phenylketonuria Medication Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Phenylketonuria Medication Market: Competitive Dashboard
14.2 Global Phenylketonuria Medication Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biomarin
14.3.2 Vitaflo
14.3.3 Mead Johnson
14.3.4 Nutricia
14.3.5 Abbott
14.3.6 Dr. Schär
14.3.7 Prominmetabolics
14.3.8 Cambrooke
14.3.9 Juvela
14.3.10 Firstplay Dietary
14.3.11 PKU Perspectives
